Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung

Journal of Thoracic Oncology

Volumn 13, Issue 5, 2018, Pages 636-648

  Kim, Hye Sook ^a   Lee, Jeong Hyeon ^b   Nam, Soo Jeong ^c   Ock, Chan Young ^d   Moon, Jae Woo ^d   Yoo, Chong Woo ^e   Lee, Geon Kook ^e   Han, Ji Youn ^e  

^a Seonam University of Medicine Myongji Hospital   (South Korea)

^b College of Medicine   (South Korea)

^c Asan Medical Center   (South Korea)

^d Theragen BiO Institute   (South Korea)

^e National Cancer Center   (South Korea)

Author keywords

Large cell neuroendocrine lung cancer; Mutation burden; Programmed cell death ligand 1; Small cell lung cancer; Tumor infiltrating immune cell

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; GENE MUTATION; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NONSYNONYMOUS MUTATION; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VOLUME; BIOSYNTHESIS; CARCINOMA; GENETICS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; CARCINOMA, NEUROENDOCRINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING;

EID: 85042202061     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2018.01.008     Document Type: Article

References (50)

1. Iyoda, A., Hiroshima, K., Nakatani, Y., Fujisawa, T., Pulmonary large cell neuroendocrine carcinoma: its place in the spectrum of pulmonary carcinoma. Ann Thorac Surg 84 (2007), 702–707.
2. Peifer, M., Fernandez-Cuesta, L., Sos, M.L., et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44 (2012), 1104–1110.
3. Ross, J.S., Wang, K., Elkadi, O.R., et al. Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol 67 (2014), 772–776.
4. Wakuda, K., Kenmotsu, H., Serizawa, M., et al. Molecular profiling of small cell lung cancer in a Japanese cohort. Lung Cancer 84 (2014), 139–144.
5. George, J., Lim, J.S., Jang, S.J., et al. Comprehensive genomic profiles of small cell lung cancer. Nature 524 (2015), 47–53.
6. Maddison, P., Newsom-Davis, J., Mills, K.R., Souhami, R.L., Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353 (1999), 117–118.
7. Rizvi, N.A., Hellmann, M.D., Snyder, A., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 12–128.
8. Sullivan, I., Kossai, M., Le Teuff, G., et al. MA11.02 Mutational burden in pulmonary neuroendocrine tumors (puNETs). J Thorac Oncol, 12, 2017, S404.
9. Rekhtman, N., Pietanza, M.C., Hellmann, M.D., et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res 22 (2016), 3618–3629.
10. Danilova, L., Wang, H., Sunshine, J., et al. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. Proc Natl Acad Sci U S A 113 (2016), E7769–E7777.
11. Peng, W., Chen, J.Q., Liu, C., et al. Loss of PTEN promotes resistance to t cell-mediated immunotherapy. Cancer Discov 6 (2016), 202–216.
12. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
13. Pedoeem, A., Azoulay-Alfaguter, I., Strazza, M., et al. Programmed death-1 pathway in cancer and autoimmunity. Clin Immunol 153 (2014), 145–152.
14. Darb-Esfahani, S., Kunze, C.A., Kulbe, H., et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 7 (2016), 1486–1499.
15. Sabari, J.K., Lok, B.H., Laird, J.H., Poirer, J.T., Rudin, C.M., Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 14 (2017), 549–561.
16. Eerola, A.K., Soini, Y., Paakko, P., A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 6 (2000), 1875–1881.
17. Ruffini, E., Asioli, S., Filosso, P.L., et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 87 (2009), 365–371 [discussion 371–362].
18. Ishii, H., Azuma, K., Kawahara, A., et al. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol 10 (2015), 426–430.
19. Schultheis, A.M., Scheel, A.H., Ozretic, L., et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 51 (2015), 421–426.
20. Komiya, T., Madan, R., PD-L1 expression in small cell lung cancer. Eur J Cancer 51 (2015), 1853–1855.
21. Berghoff, A.S., Ricken, G., Wilhelm, D., et al. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). J Neurooncol 130 (2016), 1–29.
22. Chang, Y.L., Yang, C.Y., Huang, Y.L., Wu, C.T., Yang, P.C., High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget, 2017.
23. Ott, P.A., Elez, E., Hiret, S., et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol 35 (2017), 3823–3829.
24. Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
25. Lotan, T.L., Gurel, B., Sutcliffe, S., et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 17 (2011), 6563–6573.
26. Han, J.Y., Kim, S.H., Lee, Y.S., et al. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Lung Cancer 85 (2014), 161–167.
27. Zhang, W., Meehan, J., Su, Z., et al. Whole genome sequencing of 35 individuals provides insights into the genetic architecture of Korean population. BMC Bioinformatics, 15(suppl 11), 2014, S6.
28. Berghoff, A.S., Kiesel, B., Widhalm, G., et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 17 (2015), 1064–1075.
29. Shen, J.K., Cote, G.M., Choy, E., et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2 (2014), 690–698.
30. Beckers, R.K., Selinger, C.I., Vilain, R., et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology 69 (2016), 25–34.
31. Cooper, W.A., Tran, T., Vilain, R.E., et al. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer 89 (2015), 181–188.
32. Yu, H., Boyle, T.A., Zhou, C., Rimm, D.L., Hirsch, F.R., PD-L1 expression in lung cancer. J Thorac Oncol 11 (2016), 964–975.
33. Mori, M., Ohtani, H., Naito, Y., et al. Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med 191 (2000), 113–118.
34. Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., Ueda, S., Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56 (2007), 1173–1182.
35. Kim, J.R., Moon, Y.J., Kwon, K.S., et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One, 8, 2013, e82870.
36. Del Mar Valenzuela-Membrives, M., Perea-Garcia, F., Sanchez-Palencia, A., et al. Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer. Oncotarget 7 (2016), 71608–71609.
37. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J., Schreiber, R.D., Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3 (2002), 991–998.
38. Fan, Y., Ma, K., Wang, C., et al. Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther 9 (2016), 6075–6082.
39. Reck, M., Luft, A., Szczesna, A., et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol 34 (2016), 3740–3748.
40. Reck, M., Bondarenko, I., Luft, A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 24 (2013), 75–83.
41. Antonia, S.J., Lopez-Martin, J.A., Bendell, J., et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 17 (2016), 883–895.
42. Campesato, L.F., Barroso-Sousa, R., Jimenez, L., et al. Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. Oncotarget 6 (2015), 34221–34227.
43. Madore, J., Strbenac, D., Vilain, R., et al. PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage III melanoma. Clin Cancer Res 22 (2016), 3915–3923.
44. Snyder, A., Makarov, V., Merghoub, T., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371 (2014), 2189–2199.
45. Gatalica, Z., Snyder, C., Maney, T., et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 23 (2014), 2965–2970.
46. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
47. van Rooij, N., van Buuren, M.M., Philips, D., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31 (2013), e439–e442.
48. Van Allen, E.M., Miao, D., Schilling, B., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
49. Balar, A.V., Galsky, M.D., Rosenberg, J.E., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389 (2017), 67–76.
50. Brown, S.D., Warren, R.L., Gibb, E.A., et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24 (2014), 743–750.